Diabetes Australia supporting research into cardiovascular health 8 October 2019 A new class of diabetes drugs – SGLT 2 inhibitors could have a range of benefits for cardiovascular health. With the support of a grant from the Diabetes Australia Research Trust Associate Professor Neale Cohen, from the Baker Heart and Diabetes Institute, is trying to find new therapies to improve the health of people with diabetes. SGLT2 inhibitors work by helping the kidneys lower blood glucose levels. “Recent studies into SGLT2 inhibitors have found benefits to heart health, however at this stage we don’t really understand how those benefits work,” Associate Professor Cohen said. “We want to understand how these drugs help the heart, and if they might have benefits for the heart over and above their ability to lower blood glucose levels.”
Media releases 18 November 2026 Foundayo approval a welcome addition to GLP-1 treatment options Diabetes Australia has welcomed the TGA approval of Foundayo (orforglipron), a new oral GLP-1 receptor agonist for the management of type 2 diabetes and chronic weight management in eligible adults. Continue Reading
Media releases 6 November 2026 Diabetes Australia welcomes new oral GLP-1 treatment option for Australians Diabetes Australia welcomes the Therapeutic Goods Administration’s (TGA) recent approval of a new oral formulation of Wegovy (semaglutide) as a step forward in the treatment of obesity and related chronic conditions. Continue Reading
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Goods Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading